Lymphatic filariasis is a parasitic disease caused by microscopic, thread-like worms. The adult worms only live in the human lymph system. The lymph system maintains the body's fluid balance and fights infections. Lymphatic filariasis is spread from person to person by mosquitoes.
People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.
Clear evidence that Lymphatic Filariasis (LF, commonly known as elephantiasis) can be eliminated is reported in The Lancet. LF is one of the world's most disfiguring and disabling parasitic diseases, and the target of one of the largest global public health programs using mass drug administration (MDA).
Organizers of a 20-year global effort to eliminate a parasitic infection that is a leading cause of disability have an early victory to savor: a five-year Egyptian elimination campaign has mostly succeeded, according to a new report in the March 25 issue of The Lancet.
Achieving success in the global fight against the "big three" diseases - HIV/AIDS, tuberculosis and malaria, which together account for 5.6 million deaths a year - may well require a concurrent attack on the world’s most neglected tropical diseases, says a team of researchers in the international open access journal PLoS Medicine.
"The big three" infections AIDS, TB and malaria have caught the world's attention but other disabling and fatal infectious diseases in Africa are being ignored, say three eminent tropical disease researchers in the international health journal PLoS Medicine.
Scientists at the Liverpool School of Tropical Medicine have proved that a single course of one antibiotic may hold the key to curing the parasitic worm disease Elephantiasis (lymphatic filariasis) that has been one of the most common causes of global disability since Biblical times.
A single course of one antibiotic can successfully treat elephantiasis (filariasis) - a parasitic worm disease that is one of the most common causes of global disability, concludes a study published in this week’s issue of The Lancet.
More than a billion people are at risk for infection with filarial nematodes, parasites that cause elephantiasis, African river blindness, and other debilitating diseases in more than 150 million people worldwide.
300 million people in the developing world are seriously ill from intestinal worms. Treatment is cheap and effective—and if successfully delivered with other public-health measures could make a substantial contribution to achieving many of the world’s Millennium development Goals (MDGs), concludes the lead editorial in this week’s issue of THE LANCET.
Millions of the world's poorest people are suffering needlessly from diseases that are being neglected because of the emphasis given to the "big 3" killers, HIV/AIDS, TB and Malaria, says Professor David Molyneux of the Liverpool School of Tropical Medicine.
A JCU public health expert is off to Dili, Timor Leste (formerly East Timor) to help the World Health Organisation address three serious tropical diseases: lymphatic filariasis, intestinal worms and yaws.
A memorandum which is to lead to the re-training of five million village doctors in rural China is to be signed on 23 May in Beijing, China. The memorandum goes back to the initiative of Terence Ryan, Professor of Dermatology at the University of Oxford, who has been instrumental in drawing it up and will participate in the signing.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.